Sutro Biopharma (STRO) Other Accumulated Expenses (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Other Accumulated Expenses data on file, last reported at $2.9 million in Q4 2025.

• For the quarter ending Q4 2025, Other Accumulated Expenses fell 27.34% year-over-year to $2.9 million; the trailing twelve-month figure through Dec 2025 stood at $2.9 million (down 27.34% YoY), and the FY2025 full-year result was $2.9 million, down 27.34% from the prior year.
• Other Accumulated Expenses declined to $2.9 million in Q4 2025, from $15.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $17.8 million in Q2 2025 to a low of $185000.0 in Q1 2021.
• A 5-year average of $5.0 million and a median of $3.4 million in 2024 frame the typical range for Other Accumulated Expenses.
• Across the five-year window, Other Accumulated Expenses sank 91.39% in 2021 and surged 1408.11% in 2022, its largest moves.
• Tracing STRO's Other Accumulated Expenses over 5 years: stood at $2.8 million in 2021, then grew by 12.0% to $3.1 million in 2022, then grew by 26.53% to $3.9 million in 2023, then grew by 2.87% to $4.0 million in 2024, then slipped by 27.34% to $2.9 million in 2025.
• Business Quant data shows STRO's Other Accumulated Expenses at $2.9 million in Q4 2025, $15.8 million in Q3 2025, and $17.8 million in Q2 2025.